Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Esperion Therapeutics Inc

ESPR ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: N/A

Last Close

$3.18

▲ +0.00%

Market Cap $819.46M · Vol 26.20M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$819.46M

Small Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

58.33

Momentum

Beta

1.09

vs Market

52W High

$4.18

23.83% below

52W Low

$1.11

76.18% above

Volume

26.20M

Avg 2.48M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

95.44%

Public shares

Shariah Compliance8 STANDARDS

✗ Esperion Therapeutics Inc (ESPR) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ESPR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.95%

+43.24%

-3.64%

YTD

-14.05%

+167.23%

+93.90%

-82.64%

Financials & Valuation

TTM · Annual

Total Revenue	$403.14M
Net Income	$-22,682,000.00
Revenue Growth (YoY)	+23.25%
Gross Margin	67.95%
Operating Margin	14.95%
Net Profit Margin	-5.63%
ROE	N/A
ROA · ROIC	-5.15% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1.91
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	257.69M

Technical Indicators

50-Day SMA	$3.12
200-Day SMA	$3.06
RSI (14)	58.33
Beta	1.09
52-Week High	$4.18
52-Week Low	$1.11

Volume Today	26.20M
Avg Daily Volume (30D)	2.48M
Relative Volume	10.57x
Volatility (10D)	6.49
Volatility (30D)	5.50
Free Float	95.44%

Analyst Consensus

N/A

Current Price $3.18

Mean Target N/A

52W Low$1.11 52W High$4.18

Current

Target

$1.11 $4.18

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG004KB3SZ1

ISINUS29664W1053

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cardiometabolic and rare/orphan disease therapies. It markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels who are at risk of cardiovascular disease and nasal spray, loop diuretic for the treatment of edema associated with congestive heart failure, and hepatic and renal disease. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. NEXLETOL is a first-in-class ACLY inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors. NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and cholesterol absorption in the intestine. Its Enbumyst is the FDA-approved nasal spray loop diuretic.